X
Xiaoling Zhong
Researcher at Indiana University
Publications - 17
Citations - 477
Xiaoling Zhong is an academic researcher from Indiana University. The author has contributed to research in topics: Medicine & Cachexia. The author has an hindex of 3, co-authored 6 publications receiving 284 citations. Previous affiliations of Xiaoling Zhong include Indiana University – Purdue University Indianapolis & Ohio State University.
Papers
More filters
Journal ArticleDOI
IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer
Thomas A. Mace,Reena Shakya,Jason R. Pitarresi,Benjamin Swanson,Christopher McQuinn,Shannon Loftus,Emily Nordquist,Zobeida Cruz-Monserrate,Lianbo Yu,Gregory S. Young,Xiaoling Zhong,Teresa A. Zimmers,Michael C. Ostrowski,Thomas Ludwig,Mark Bloomston,Tanios Bekaii-Saab,Gregory B. Lesinski +16 more
TL;DR: Preclinical results indicate that targeted inhibition of IL-6 may enhance the efficacy of anti-PD-L1 in PDAC, and improve overall survival in KPC-Brca2 mice.
Journal ArticleDOI
The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy.
Xiaoling Zhong,Xiaoling Zhong,Marianne Pons,Christophe Poirier,Yanlin Jiang,Jianguo Liu,George E. Sandusky,Safi Shahda,Attila Nakeeb,C. Max Schmidt,Michael G. House,Eugene P. Ceppa,Nicholas J. Zyromski,Yunlong Liu,Guanglong Jiang,Marion E. Couch,Leonidas G. Koniaris,Teresa A. Zimmers +17 more
TL;DR: Pancreatic ductal adenocarcinoma is a particularly lethal malignancy partly due to frequent, severe cachexia, and serum activin correlates with cachexia and mortality, while exogenous activin causes cachexia in mice.
Journal ArticleDOI
Sex Differences in Cancer Cachexia
Xiaoling Zhong,Teresa A. Zimmers +1 more
TL;DR: This review aims to highlight the sex differences in manifestations of cancer cachexia in patients, rodent models, and the current understanding of the potential mechanisms accounting for these differences.
Journal ArticleDOI
Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin
Xiaoling Zhong,Ashok Narasimhan,Libbie M. Silverman,Andrew N. Young,Safi Shahda,Sheng Liu,Jun Wang,Yunlong Liu,Leonidas G. Koniaris,Teresa A. Zimmers +9 more
TL;DR: The reproductive hormone and cytokine Activin is a mediator of PDAC cachexia and Activin receptor targeting was clinically tested for cancer cachexia therapy.
Posted ContentDOI
The systemic activin response to pancreatic cancer: Implications for effective cancer cachexia therapy
Xiaoling Zhong,Marianne Pons,Christophe Poirier,Yanlin Jiang,Jianguo Liu,George E. Sandusky,Yunlong Liu,Guanglong Jiang,Marion E. Couch,Leonidas G. Koniaris,Teresa A. Zimmers +10 more
TL;DR: The results indicate that PDAC induces a systemic activin response, leading to cachexia, and that activin targets might include organs beyond muscle, and targeting of both tumor-derived and host-derived activins could improve cachexia therapy.